Cancer Stem Cell News Volume 10.20 | May 26 2021


    2021-05-26 | CSCN 10.20

    Cancer Stem Cell News by STEMCELL Technologies
    Vol. 10.20 – 26 May, 2021

    Exosomal S100A4 Derived from Highly Metastatic Hepatocellular Carcinoma Cells Promotes Metastasis by Activating STAT3

    Scientists found that exosomal S100 calcium-binding protein A4 (S100A4) could induce the expression of osteopontin, along with other tumor metastasis/stemness-related genes.
    [Signal Transduction and Targeted Therapy]

    Full Article

    How to prioritize and manage your research projects
    PUBLICATIONSRanked by the impact factor of the journal

    FMR1/circCHAF1A/miR-211-5p/HOXC8 Feedback Loop Regulates Proliferation and Tumorigenesis via MDM2-Dependent p53 Signaling in GSCs

    The novel feedback loop among FMR1, circRNA-CHAF1A (circCHAF1A), miR-211-5p, and HOXC8 in glioma stem cells (GSCs) could facilitate the proliferation and tumorigenesis of glioma and GSCs


    GABRP Sustains the Stemness of Triple-Negative Breast Cancer Cells through EGFR Signaling

    The authors found that the gamma-aminobutyric acid type A receptor π subunit (GABRP), as a membrane protein enriched in triple-negative breast cancer stem cells, interacted with epidermal growth factor receptor (EGFR) and significantly sustained its expression, resulting in stemness maintenance and chemotherapy resistance.
    [Cancer Letters]


    UPF1 Promotes Chemoresistance to Oxaliplatin through Regulation of TOP2A Activity and Maintenance of Stemness in Colorectal Cancer

    UPF1 enhanced chemoresistance to oxaliplatin in colorectal cancer, which may result from regulation of TOP2A activity and maintenance of stemness.
    [Cell Death & Disease]

    Full Article

    RNA-Sequencing of Long-Term Label-Retaining Colon Cancer Stem Cells Identifies Novel Regulators of Quiescence

    Using colon cancer patient-derived organoids and xenografts, researchers identified rare long-term label-retaining quiescent CSCs that could re-enter the cell cycle to generate new tumors.

    AbstractFull ArticleGraphical Abstract

    The Inhibition of ABCB1/MDR1 or ABCG2/BCRP Enables Doxorubicin to Eliminate Liver Cancer Stem Cells

    Scientists explored the role of inhibition of MDR1 or ABCG2 in sensitizing liver CSCs to doxorubicin, the most frequently used chemotherapeutic agent in treating liver cancer.
    [Scientific Reports]

    Full Article

    A Novel Synthetic Microtubule Inhibitor Exerts Antiproliferative Effects in Multidrug Resistant Cancer Cells and Cancer Stem Cells

    The novel microtubule inhibitor, 5-(N-methylmaleimid-3-yl)-chromone suppressed the growth and sphere-forming activity of CSCs.
    [Scientific Reports]

    Full Article

    DYRK1A Is Required for Maintenance of Cancer Stemness, Contributing to Tumorigenic Potential in Oral/Oropharyngeal Squamous Cell Carcinoma

    The authors reported a novel role of DYRK1A in maintaining tumor growth and stemness of oral/oropharyngeal squamous cell carcinoma cells.
    [Experimental Cell Research]

    Full Article

    Genetic Manipulation of Adhesion GPCR CD97/ADGRE5 Modulates Invasion in Patient-Derived Glioma Stem Cells

    Researchers examined CD97 function in primary patient-derived glioma stem cells obtained from five glioblastoma tumors, belonging to three major genetic subtypes.
    [Journal of Neuro-Oncology]


    Webinar: Organoids as Models for Human Disease

    Recent Progress on Targeting Leukemia Stem Cells

    Scientists summarize the targeted therapy approaches for the removal of leukemic stem cells (LSCs) through surface markers including immune checkpoint molecules, pathways influencing LSC survival, or the survival microenvironment of LSCs.
    [Drug Discovery Today]


    MicroRNA-1: Diverse Role of a Small Player in Multiple Cancers

    Investigators focus on the different antitumorigenic and therapeutic aspects of miR-1, including how it regulates tumor development and associated immunomodulatory functions.
    [Seminars in Cell & Developmental Biology]



    KAHR Receives Investment from Cancer Focus Fund to Support Phase I/II Study of KAHR’s Lead Anti-CD47 Candidate in Blood Cancers

    KAHR and Cancer Focus Fund, LP announced that Cancer Focus Fund is investing $5 million to finance a clinical trial of KAHR’s lead anti-CD47 candidate, DSP107, in blood cancers.
    [KAHR (PR Newswire, LLC)]

    Press Release

    AbbVie Receives European Commission Approval of VENCLYXTO® (Venetoclax) in Combination with a Hypomethylating Agent for Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

    AbbVie, Inc. announced that the European Commission has approved VENCLYXTO® in combination with a hypomethylating agent, azacitidine or decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.
    [AbbVie, Inc.]

    Press Release


    Origins of Cancer

    July 22 – 23, 2021

    > See All Events


    Postdoctoral Position – Stemness Control in Pluripotent and Cancer Cells

    Columbia University Medical Center – New York, New York, United States

    Research Associate – Senescence in Cancer

    University of Cambridge – Cambridge, England, United Kingdom

    Faculty Positions – Immuno-Oncology

    Medical College of Wisconsin – Milwaukee, Wisconsin, United States

    Research Associate – Cancer Stem Cell Biology

    City of Hope – Duarte, California, United States

    Postdoctoral Scientist – Non-Classical Mechanisms of Therapy Resistance

    Cedars-Sinai – Los Angeles, California, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cancer Stem Cell News Twitter